Open AccessPreclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections
Author(s) -
Laurent Chorro,
Zhenghui Li,
Ling Chu,
Suddham Singh,
Jinjie Gu,
Jin Hwan Kim,
Kaushik Dutta,
Rosalind Pan,
Srinivas Kodali,
Duston Ndreu,
Axay Patel,
Julio C. Hawkins,
Chris Ponce,
Natalie Silmon de Monerri,
David Keeney,
Arthur Illenberger,
Claire Jones,
Lubomira Andrew,
Jason Lotvin,
A. Krishna Prasad,
Isis Kanevsky,
Kathrin U. Jansen,
Annaliesa S. Anderson,
Robert G. K. Donald
Publication year - 2022
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.00022-22
Subject(s) - immunogenicity , microbiology and biotechnology , antigen , glycoconjugate , biology , escherichia coli , conjugate , epitope , virology , serotype , immunology , biochemistry , gene , mathematical analysis , mathematics
Multivalent O-antigen polysaccharide glycoconjugate vaccines are under development to prevent invasive infections caused by pathogenicEnterobacteriaceae . Sequence type 131 (ST131)Escherichia coli of serotype O25b has emerged as the predominant lineage causing invasive multidrug-resistant extraintestinal pathogenicE. coli (ExPEC) infections. We observed the prevalence ofE. coli O25b ST131 among a contemporary collection of isolates from U.S. bloodstream infections from 2013 to 2016 (n = 444) and global urinary tract infections from 2014 to 2017 (n = 102) to be 25% and 24%, respectively.